Form 8-K

8-K — GT Biopharma, Inc.

Accession: 0001493152-26-041333

Filed: 2026-09-03

Period: 2026-09-02

CIK: 0000109657

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Material Modifications to Rights of Security Holders

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

EX-3.2 (ex3-2.htm)

EX-3.3 (ex3-3.htm)

EX-3.4 (ex3-4.htm)

EX-3.5 (ex3-5.htm)

EX-3.6 (ex3-6.htm)

EX-3.7 (ex3-7.htm)

EX-3.8 (ex3-8.htm)

EX-3.9 (ex3-9.htm)

EX-3.10 (ex3-10.htm)

EX-3.11 (ex3-11.htm)

EX-3.12 (ex3-12.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0000109657

2026-09-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 2, 2026

Biopharma, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

(State

or other Jurisdiction of Incorporation)

1-40023

94-1620407

(Commission

File

Number)

(IRS

Employer

Identification

No.)

N/A1

(Address

of Principal Executive Offices and zip code)

(415)

919-4040

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, $0.001 par value

GTBP

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Effective as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes

of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended,

any stockholder communication required to be sent to the Company’s principal executive offices may be directed to 505 Montgomery

Street, 10th Floor, San Francisco, California 94111, or by email to auditcommittee@gtbiopharma.com.

Item

3.03. Material Modifications to Rights of Security Holders.

the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated

herein by reference.

Item

5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Certificates

of Elimination - Preferred Stock

September 2, 2026, GT Biopharma, Inc. (the “Company”) filed Certificates of Elimination (collectively, the “Certificates

of Elimination”) to the Restated Certificate of Incorporation of the Company (the “Charter”) with the Secretary of

State of the State of Delaware. The Certificates of Elimination eliminate from the Charter all matters set forth in the applicable Certificates

of Designations with respect to the following series of preferred stock: (i) the Series A Preferred Stock; (ii) the Series B Preferred

Stock; (iii) the Series C Preferred Stock; (iv) the Series D Preferred Stock; (v) the Series E Preferred Stock; (vi) the Series F Preferred

Stock; (vii) the Series G Preferred Stock; (viii) the Series H Preferred Stock; (ix) the Series I Preferred Stock; (x) the Series J-1 Preferred Stock; and (xi) the Series K Preferred Stock (collectively, the “Eliminated Preferred Stock”).

All

outstanding shares of the Series C Preferred Stock were converted in accordance with their terms on September 2, 2026. No shares of any

series of Eliminated Preferred Stock were outstanding immediately before the filing of the Certificates of Elimination.

The

forgoing description of the Certificates of Elimination does not purport to be complete and is subject to, and is qualified in its entirety

by reference to, the full text of the Certificates of Elimination, which is attached as Exhibits 3.1 through 3.11 to this Current

Report on Form 8-K, and is incorporated herein by reference.

Certificate

of Amendment - Reverse Stock Split and Reduction in Authorized Shares

addition to filing the Certificates of Elimination, on September 2, 2026, the Company also filed a Certificate of Amendment (the “Certificate

of Amendment”) to the Charter with the Secretary of State of the State of Delaware to effect a (i) reverse stock split of the Company’s

common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-25 (the “Reverse Stock Split”)

and (ii) simultaneous reduction of the authorized shares of Common Stock to 25,000,000 and preferred stock to 1,500,000 (the “Reduction

in Authorized Shares” and, together with the Reverse Stock Split, the “Charter Actions”).

The

Certificate of Amendment provides that the Reverse Stock Split will become effective as of 12:01 a.m. Eastern Time on September 8, 2026

(the “Effective Time”), at which time every twenty-five (25) shares of issued and outstanding Common Stock will be automatically

combined into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. The Certificate of

Amendment provides that no fractional shares will be issued in connection with the Reverse Stock Split. In lieu thereof, the aggregate

of all fractional shares otherwise issuable to the holders of record of old Common Stock will be issued to the Company’s transfer

agent, as exchange agent, for the accounts of all holders of record of old Common Stock otherwise entitled to have a fraction of a share

issued to them. The sale of all fractional interests will be effected by the exchange agent as soon as practicable after the Effective

Time on the basis of prevailing market prices of the applicable new Common Stock. After such sale, the exchange agent will pay to such

holders of record their pro rata share of the net proceeds derived from the sale of the fractional interests.

Trading

of the Common Stock on the Nasdaq Capital Market on a split-adjusted basis will commence at market open on September 8, 2026. The new

CUSIP number for the Common Stock following the Reverse Stock Split is 36254L 407.

a result of the Reverse Stock Split, the issued and outstanding shares of Common Stock will be decreased from approximately 45,109,497

pre-split shares to approximately 1,804,379 post-split shares, subject to adjustment for fractional shares.

The

Reverse Stock Split will apply to the Company’s outstanding convertible securities, warrants, stock options and restricted stock.

The number of shares of Common Stock into which these outstanding securities are convertible or exercisable will be adjusted proportionately

as a result of the Reverse Stock Split. The conversion prices of any outstanding convertible securities and the exercise prices of any

outstanding warrants or stock options will also be proportionately adjusted in accordance with the terms of those securities and the

Company’s equity incentive plans.

previously disclosed, at the Company’s annual meeting of stockholders held on August 14, 2026 (the “Meeting”), the

Company’s stockholders approved, among other things, a proposal authorizing the Company to effect the Reverse stock Split at a

ratio in the range of 1-for-10 to 1-for-30, with the final ratio to be determined in the discretion of the Company’s board of directors

(the “Board”) and a simultaneous reduction in authorized shares, with such actions to be effective at such time and date,

if at all, as determined by the Board within one year after the conclusion of the Meeting. Subsequently on August 27, 2026, the Board

approved the final reverse stock split ratio of 1-for-25 (the “Reverse Stock Split Ratio”).

Simultaneously

with the Reverse Stock Split, as a result of the Reduction in Authorized Shares, the total authorized shares of capital stock was reduced

from 265,000,000 shares to 26,500,000 shares, consisting of 25,000,000 shares of Common Stock and 1,500,000 shares of preferred stock.

The

forgoing description of the Charter Actions effected in the Certificate of Amendment does not purport to be complete and is subject to,

and is qualified in its entirety by reference to, the full text of the Certificate of Amendment, which is attached as Exhibit 3.12

to this Current Report on Form 8-K, and is incorporated herein by reference.

Item

8.01. Other Events.

The

information in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

The

Company has registration statements on Form S-3 (File No. 333-285618), registration statements on Form S-1 (File Nos. 333-292856, 333-291060,

333-287963, 333-280326, 333-255429, 333-252973 and 333-251311) and registration statements on Form S-8 (File No. 333-266316) (collectively,

the “Registration Statements”) on file with the Securities and Exchange Commission (the “SEC”). SEC regulations

permit the Company to incorporate by reference future filings made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the

Securities and Exchange Act of 1934, as amended, prior to the termination of the offerings covered by registration statements filed on

Form S-3, Form S-1 and/or Form S-8. The information incorporated by reference is considered part of the prospectus included within each

of those registration statements. Information in this Item 8.01 is intended to be automatically incorporated by reference into each of

the active Registration Statements, thereby amending them. Pursuant to Rule 416(b) under the Securities Act of 1933, as amended, the

amount of undistributed shares of Common Stock deemed covered by the Registration Statements are proportionately reduced as of the effective

time of the Reverse Stock Split at the Reverse Stock Split Ratio.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

Number

Description

3.1

Certificate of Elimination relating to the Series A Preferred Stock, dated September 2, 2026

3.2

Certificate of Elimination relating to the Series B Preferred Stock, dated September 2, 2026

3.3

Certificate of Elimination relating to the Series C Preferred Stock, dated September 2, 2026

3.4

Certificate of Elimination relating to the Series D Preferred Stock, dated September 2, 2026

3.5

Certificate of Elimination relating to the Series E Preferred Stock, dated September 2, 2026

3.6

Certificate of Elimination relating to the Series F Preferred Stock, dated September 2, 2026

3.7

Certificate of Elimination relating to the Series G Preferred Stock, dated September 2, 2026

3.8

Certificate of Elimination relating to the Series H Preferred Stock, dated September 2, 2026

3.9

Certificate of Elimination relating to the Series I Preferred Stock, dated September 2, 2026

3.10

Certificate of Elimination relating to the Series J-1 Preferred Stock, dated September 2, 2026

3.11

Certificate of Elimination relating to the Series K Preferred Stock, dated September 2, 2026

3.12

Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc.

104

Cover

Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

BIOPHARMA, INC.

Date:

September 3, 2026

By:

/s/

Alan Urban

Alan

Urban

Chief

Financial Officer

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit 3.1

CERTIFICATE

OF ELIMINATION

Series

A Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series A Preferred Stock are outstanding and that no shares of the

Series A Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series A Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

A Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series A Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.2

Filename: ex3-2.htm · Sequence: 3

Exhibit

3.2

CERTIFICATE

OF ELIMINATION

Series

B Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series B Preferred Stock are outstanding and that no shares of the

Series B Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series B Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

B Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series B Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.3

Filename: ex3-3.htm · Sequence: 4

Exhibit

3.3

CERTIFICATE

OF ELIMINATION

Series

C Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series C Preferred Stock are outstanding and that no shares of the

Series C Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series C Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

C Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series C Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.4

Filename: ex3-4.htm · Sequence: 5

Exhibit

3.4

CERTIFICATE

OF ELIMINATION

Series

D Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series D Preferred Stock are outstanding and that no shares of the

Series D Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series D Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

D Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series D Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.5

Filename: ex3-5.htm · Sequence: 6

Exhibit

3.5

CERTIFICATE

OF ELIMINATION

Series

E Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series E Preferred Stock are outstanding and that no shares of the

Series E Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series E Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

E Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series E Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.6

Filename: ex3-6.htm · Sequence: 7

Exhibit 3.6

CERTIFICATE

OF ELIMINATION

Series

F Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series F Preferred Stock are outstanding and that no shares of the

Series F Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series F Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

F Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series F Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.7

Filename: ex3-7.htm · Sequence: 8

Exhibit

3.7

CERTIFICATE

OF ELIMINATION

Series

G Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series G Preferred Stock are outstanding and that no shares of the

Series G Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series G Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

G Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series G Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.8

Filename: ex3-8.htm · Sequence: 9

Exhibit

3.8

CERTIFICATE

OF ELIMINATION

Series

H Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series H Preferred Stock are outstanding and that no shares of the

Series H Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series H Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

H Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series H Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.9

Filename: ex3-9.htm · Sequence: 10

Exhibit

3.9

CERTIFICATE

OF ELIMINATION

Series

I Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series I Preferred Stock are outstanding and that no shares of the

Series I Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series I Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant

to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s

Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series

I Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series I Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.10

Filename: ex3-10.htm · Sequence: 11

Exhibit 3.10

CERTIFICATE OF ELIMINATION

Series J-1

Preferred stock

GT BIOPHARMA,

INC.

(Pursuant to Section 151(g) of the

Delaware General Corporation Law)

GT Biopharma, Inc., a Delaware corporation (the “Company”),

does hereby certify that the following resolutions were duly adopted by the Company’s Board of Directors:

NOW, THEREFORE, BE IT RESOLVED,

that no shares of the Company’s Series J-1 Preferred Stock are outstanding and that no shares of the Series J-1 Preferred Stock

will be issued subject to the Certificate of Designations previously filed with respect to the Series J-1 Preferred Stock;

RESOLVED FURTHER, that

each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the name and on behalf

of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination pursuant to Section 151(g) of

the Delaware General Corporation Law setting forth these resolutions in order to eliminate from the Company’s Restated Certificate

of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect to the Series J-1 Preferred Stock;

and

RESOLVED FURTHER, that

when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of eliminating from the

Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with respect

to the Series J-1 Preferred Stock.

[Signature Page Follows]

IN WITNESS WHEREOF, the Company has caused this Certificate of Elimination

to be executed by its duly authorized officer on the date set forth below.

BIOPHARMA, INC.

By:

/s/

Alan Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.11

Filename: ex3-11.htm · Sequence: 12

Exhibit

3.11

CERTIFICATE

OF ELIMINATION

Series

K Preferred stock

BIOPHARMA, INC.

(Pursuant

to Section 151(g) of the

Delaware

General Corporation Law)

Biopharma, Inc., a Delaware corporation (the “Company”), does hereby certify that the following resolutions were duly

adopted by the Company’s Board of Directors:

NOW,

THEREFORE, BE IT RESOLVED, that no shares of the Company’s Series K Preferred Stock are outstanding and that no shares of the

Series K Preferred Stock will be issued subject to the Certificate of Designations previously filed with respect to the Series K Preferred

Stock;

RESOLVED

FURTHER, that each officer of the Company (whether acting alone or together with any other officer) is hereby authorized, in the

name and on behalf of the Company, to file with the Secretary of State of the State of Delaware a Certificate of Elimination

pursuant to Section 151(g) of the Delaware General Corporation Law setting forth these resolutions in order to eliminate from

the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations with

respect to the Series K Preferred Stock; and

RESOLVED

FURTHER, that when such Certificate of Elimination setting forth these resolutions becomes effective, it shall have the effect of

eliminating from the Company’s Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations

with respect to the Series K Preferred Stock.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on the date

set forth below.

BIOPHARMA, INC.

By:

/s/

Alan

Urban

Name:

Alan

Urban

Title:

CFO

Date:

September

2, 2026

EX-3.12

Filename: ex3-12.htm · Sequence: 13

Exhibit 3.12

CERTIFICATE

OF AMENDMENT OF

RESTATED

CERTIFICATE OF INCORPORATION OF

BIOPHARMA, INC.

Biopharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the

“Corporation”), does hereby certify:

FIRST:

That the Board of Directors of the Corporation duly adopted a resolution by the unanimous written consent of its members proposing and

declaring fair, reasonable and advisable and in the best interest of the Company and its stockholders the following amendment to the

restated certificate of incorporation of the Corporation (as amended, the “Certificate of Incorporation”) and recommending

that the stockholders of the Corporation consider and approve the resolution. The resolution setting forth the proposed amendment is

as follows:

RESOLVED,

that the Certificate of Incorporation be amended by replacing in its entirety the first and second paragraphs of Article FOURTH so that,

as amended, the paragraphs shall be and read as follows:

“I.

COMMON STOCK

Upon

this Certificate of Amendment of Restated Certificate of Incorporation of Corporation (this “Certificate of Amendment”) becoming

effective pursuant to the Delaware General Corporation Law (the “Effective Time”), each twenty-five (25) shares of Common

Stock issued and outstanding (the “Old Common Stock”) immediately prior to the Effective Time shall automatically without

further action on the part of the Company or any holder of Old Common Stock, be combined and changed into one (1) duly authorized, fully

paid and non-assessable share of new common stock (the “New Common Stock”) (the “Stock Combination”). From and

after the Effective Time, certificates representing Old Common Stock shall represent the number of whole shares of New Common Stock into

which such Old Common Stock shall have been combined pursuant to this Certificate of Amendment. There shall be no fractional shares issued

with respect to New Common Stock. In lieu thereof, the aggregate of all fractional shares otherwise issuable to the holders of record

of Old Common Stock shall be issued to the Corporation’s transfer agent (the “Exchange Agent”), as exchange agent,

for the accounts of all holders of record of Old Common Stock otherwise entitled to have a fraction of a share issued to them. The sale

of all fractional interests will be effected by the Exchange Agent as soon as practicable after the Effective Time on the basis of prevailing

market prices of the applicable New Common Stock at the time of sale. After such sale and upon the surrender of the stockholders’

stock certificates, the Exchange Agent will pay to such holders of record their pro rata share of the net proceeds derived from the sale

of the fractional interests. After giving effect to the Stock Combination, the Company is authorized to issue a total of 25,000,000 shares

of Common Stock, $0.001 par value per share. Dividends may be paid on the Common Stock as, when and if declared by the Board of Directors,

out of any funds of the Company legally available for the payment of such dividends, and each share of Common Stock will be entitled

to one vote on all matters on which such stock is entitled to vote.

II.

PREFERRED STOCK

After

giving effect to the Stock Combination, the Company is authorized to issue a total of 1,500,000 shares of Preferred Stock ($0.01 par

value), each of which shares of Preferred Stock may be issued in one or more series of stock within the class of Preferred Stock. Each

series may have such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating,

optional or other special rights, and qualifications, limitations or restrictions thereof, as shall be stated and expressed in the resolution

or resolutions providing for the issue of such stock adopted by the Board of Directors pursuant to authority hereby expressly vested

in it by the provisions of this Restated Certificate of Incorporation.”

SECOND:

That thereafter pursuant to a resolution of the Board of Directors of the Corporation, said amendment was submitted to the stockholders

of the Corporation for their approval, and was duly adopted in accordance with the provisions of Section 242 of the General Corporation

Law of the State of Delaware.

THIRD:

That this Certificate of Amendment of Restated Certificate of Incorporation shall be effective on September 8, 2026 at 12:01, Eastern

Standard Time.

A-1

WITNESS WHEREOF, the undersigned authorized officer of the Corporation has executed this Certificate of Amendment to the Restated

Certificate of Incorporation as of September 2, 2026.

BIOPHARMA, INC.

By:

/s/

Michael Breen

Name:

Michael

Breen

Title:

Executive

Chairman of the Board of Directors and Chief Executive Officer

A-2

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 29

v3.26.1

Cover

Sep. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 02, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

1-40023

Entity Registrant Name

Biopharma, Inc.

Entity Central Index Key

0000109657

Entity Tax Identification Number

94-1620407

Entity Incorporation, State or Country Code

Entity Address, Address Line One

505 Montgomery

Street

Entity Address, Address Line Two

10th Floor

Entity Address, City or Town

San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94111

City Area Code

(415)

Local Phone Number

919-4040

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, $0.001 par value

Trading Symbol

GTBP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration